Medical Writing Risk Management Using social media as the patient's voice in the benefit-risk assessment of drugs: Are we ready?

Volume 24, Issue 2 - Risk Management

Using social media as the patient's voice in the benefit-risk assessment of drugs: Are we ready?


There is no doubt that the public interest in healthcare-related issues is growing. This, coupled with the surge in the use of social media, leaves the pharmaceutical industry with a set of unique opportunities and challenges. The screening and reporting of adverse drug reactions (ADRs) is of vital importance, and Marketing Authorisation Holders (MAHs) have a responsibility and liability for their drugs. Patients increasingly use social media to share their healthcare experiences, and this is a welcome opportunity for MAHs to learn more about the real-world experience of their products. However, currently this source for ADR reporting is largely underutilised; partly because the data generated are unstructured, but also because our technology for assessing and analysing this information is lagging behind. There is an urgent need for policy, methods, guidelines, and technology platforms to allow patients' voices through social media to be adequately ‘heard’ and incorporated into the benefit-risk assessment of drugs.

Download the full article


  1. Safety of medicines – A guide to detecting and reporting adverse drug reactions – why health professionals need to take action. World Health Organization [2002; cited 2015 Jan 28]. Available from:
  2. The safety of medicines in public health programmes: Pharmacovigilance an essential tool. World Health Organization [2006; cited 2015 Jan 28]. Available from:
  3. FDA adverse event reporting systems (FEARS). US Food and Drug Administration (FDA) [cited 2015 Jan 28]. Available from:
  4. MHRA adverse drug reactions. Medicines and Healthcare Products Regulatory Agency [cited 2015 Jan 28]. Available from:
  5. Wikibon Blog. The big list of big data infographics [2012 July 24; cited 2015 Feb 09]. Available from:
  6. IACP Center for Social Media. Fun facts. International Association of Chiefs of Police [2010–2015; cited 2015 Feb 09]. Available from:
  7. Wikibon Blog. A comprehensive list of big data statistics [2012 Aug 1; cited 2015 Feb 09]. Available from:
  8. Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, et al. Digital drug safety surveillance: Monitoring pharmaceutical products in twitter. Drug Saf. 2014;37(5):343–50.
  9. McGregor F, Somner JE, Bourne RR, Munn-Giddings C, Shah P, Cross V. Social media use by patients with glaucoma: what can we learn? Ophthalmic Physiol Opt. 2014;34(1):46–52.
  10. Banerjee AK, Ingate S. Web-based patient-reported outcomes in drug safety and risk management: Challenges and opportunities? Drug Saf. 2012;35(6):437–46.
  11. Wu H, Fang H, Stanhope SJ. Exploiting online discussions to discover unrecognized drug side effects. Methods Inf Med. 2013;52(2):152–9.
  12. Mao JJ, Chung A, Benton A, Hill S, Ungar L, Leonard CE, et al. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf. 2013;22(3):256–62.
  13. Vaughan Sarrazin MS, Cram P, Mazur A, Ward M, Reisinger HS. Patient perspectives of dabigatran: Analysis of online discussion forums. Patient. 2014;7(1):47–54.
  14. Abou Taam M, Rossard C, Cantaloube L, Bouscaren N, Roche G, Pochard L, et al. Analysis of patients’ narratives posted on social media websites on benfluorex's (Mediator®) withdrawal in France. J Clin Pharm Ther. 2014;39(1):53–5.



Risk Management
President's Message
The changing face of (benefit-)risk management
Pharmacovigilance medical writing: An evolving profession
A shot at demystifying the risk management plan for medical writers
Using social media as the patient's voice in the benefit-risk assessment of drugs: Are we ready?
Special section: Winners of the Geoff Hall Scholarship essay competition
News from the EMA
Profile: An interview with Ingrid Edsman on why attending EMWA conferences is so rewarding!
The Webscout
In the Bookstores
Regulatory Writing: Review process in regulatory writing
Lingua Franca and Beyond
Gained in Translation
Manuscript Writing
English Grammar and Style: Revising medical writing Reasons not rules: Backtracking, pronoun-induced Part 3 - Double syntactic unit revision and syntactic position revision
Out On Our Own


The Write Stuff Archive Contact Instructions for Authors Article Template (Word) Journal Policies

Editoral Board


Raquel Billiones


Evguenia Alechine

Jonathan Pitt

Managing Editor

Victoria White

Deputy Managing Editor

Alicia Brooks Waltman

Associate Editors

Anuradha Alahari

Jennifer Bell

Nicole Bezuidenhout

Claire Chang

Barbara Grossman

Sarah Milner

John Plant

Sampoorna Rappaz

Amy Whereat

Section Editors

Daniela Kamir


Jennifer Bell


Nicole Bezuidenhout 

Digital Communication

Somsuvro Basu

EMWA News 

Ana Sofia Correia 

Gained in Translation

Ivana Turek

Getting Your Foot in the Door

Wendy Kingdom / Amy Whereat

Good Writing Practice

Alison McIntosh 

In the Bookstores

Maria Kołtowska-Häggström

Lingua Franca and Beyond

Maddy Dyer


Lisa Chamberlain-James

Medical Communications/Writing for Patients

Payal Bhatia

Medical Devices

Evguenia Alechine

My First Medical Writing

Anuradha Alahari

News from the EMA

Adriana Rocha


Tiziana von Bruchhausen


Clare ChangZuo Yen Lee 

Regulatory Matters

Sam Hamilton

Regulatory Public Disclosure

Claire Gudex

Teaching Medical Writing

Louisa Ludwig-Begall / Sarah Kabani

The Crofter: Sustainable Communications

Louisa Marcombes

Veterinary Writing

Editors Emeritus

Elise Langdon-Neuner

Phil Leventhal

Layout Designer

Chris Monk